Oncology ImagingArchives
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)
Oncology Imaging 1 min.
Recent studies indicate that early changes on 2-deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) predict response to human epidermal growth factor receptor 2 (HER2)-directed therapy. EA1211/DIRECT is a multicenter, single-arm, primary imaging phase 2 study enrolling...
Predictive value of 18F-FDG PET/CT metabolic parameters for gastric cancer patients’ microsatellite instability status
Oncology Imaging 4 min.
Gastric cancer (GC) is a common disease of the digestive system, with a high incidence rate and mortality. In 2020, there will be 1.09 million new cases of gastric cancer in the world, accounting for 6% of new tumor cases. The incidence rate and mortality of gastric cancer ranked fifth and third...
[18F]Tetrafluoroborate PET/CT for detecting differentiated thyroid cancer: phase-II study protocol
Oncology Imaging 1 min.
This study aims to evaluate the diagnostic potential of [F]TFB PET/CT for detecting pre-operative lymph node metastases and predicting [I] therapy response in differentiated thyroid cancer (DTC). This prospective, multicenter phase-2 clinical trial includes adult patients with DTC and pathologically...
Enhancing risk stratification in diabetic gastric cancer: muscle-fat ratio from photon-counting CT as a predictor of postoperative complications
Oncology Imaging 4 min.
Gastric cancer remains a major global health concern, with an estimated 1.09 million new cases and 768,000 deaths annually, ranking as the fourth most prevalent cancer and the second leading cause of cancer-related mortality worldwide [1, 2]. Emerging evidence highlights the multifactorial determinants...
